0001841330 1 2025-11-26 2025-11-26 0001841330 2 2025-11-26 2025-11-26 0001841330 3 2025-11-26 2025-11-26 0001841330 2025-11-26 2025-11-26 iso4217:USD pure shares S-1/A EX-FILING FEES 0001841330 333-291611 N/A N/A S-1 Pasithea Therapeutics Corp. false Equity Common Stock, par value $0.0001 per share ("Common Stock") true 60000000.00 0.0001381 8286.00 false Equity Pre-Funded Warrants to purchase Common Stock true 0.00 0.0001381 0.00 false Equity Common Stock underlying the Pre-Funded Warrants true 0.00 0.0001381 0.00 60000000.00 8286.00 2882.84 5403.16 Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended (the “Securities Act”).<br/><br/>Pursuant to Rule 416 under the Securities Act, this registration statement shall also cover an indeterminable number of additional shares of the registrant’s securities that become issuable by reason of any stock splits, stock dividends or similar transactions. Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended (the “Securities Act”).<br/><br/>The proposed maximum aggregate offering price of the Common Stock to be issued in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any Pre-Funded Warrants issued in the offering, and the proposed maximum aggregate offering price of the Pre-Funded Warrants to be issued in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any Common Stock issued in the offering. Accordingly, the proposed maximum aggregate offering price of the Common Stock and Pre-Funded Warrants (including the Common Stock issuable upon exercise of the Pre-Funded Warrants), if any, is $60,000,000.<br/><br/>No separate registration fee is payable pursuant to Rule 457(g) under the Securities Act. Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended (the “Securities Act”).<br/><br/>The proposed maximum aggregate offering price of the Common Stock to be issued in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any Pre-Funded Warrants issued in the offering, and the proposed maximum aggregate offering price of the Pre-Funded Warrants to be issued in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any Common Stock issued in the offering. Accordingly, the proposed maximum aggregate offering price of the Common Stock and Pre-Funded Warrants (including the Common Stock issuable upon exercise of the Pre-Funded Warrants), if any, is $60,000,000.